EUVIMEDEUVIMED entdecken
Beobachtungsstudie

Prognostic Value of Initial Imaging and PSA Change with [ 177 Lu]Lu-PSMA-617 Radiopharmaceutical Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: A ProsTIC Registry Analysis

David C Chen, James P Buteau, Nathan Papa, Tim Akhurst, Ramin Alipour, Neeraja Bollampally, Anthony Cardin, Michal Eifer, Sebastián Casanueva Eliceiry, Price Jackson, Kerry Jewell, Raghava Kashyap und 11 weitere

Journal of Nuclear Medicine · 2025-12 · 66 (12) · 1914-1920

DOI: 10.2967/jnumed.125.270804 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 09.10.2025. Verfasst von David C Chen und 22 weiteren Autor:innen. Beteiligte Einrichtung: Prostate Cancer Theranostics and Imaging Centre of Excellence, Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, Par…. Hauptthemen laut MEDLINE: Dipeptides, Heterocyclic Compounds, 1-Ring, Lutetium, Prostate-Specific Antigen. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 28 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

[177Lu]Lu-PSMA-617 radiopharmaceutical therapy improves survival and quality of life in patients with metastatic castration-resistant prostate cancer. We assessed whether patients who did not achieve an early prostate-specific antigen (PSA) decline after the first cycle (C1) benefited from further [177Lu]Lu-PSMA-617.

Methods

We analyzed patients with metastatic castration-resistant prostate cancer participating in a registry of [177Lu]Lu-PSMA-617 (ProsTIC registry, NCT04769817). Patients with a PSA either rising (≥25% increase from baseline) or stable (30% decrease to 25% increase from baseline) within 28 d of starting treatment (C1) and consequently received a second dose (cycle 2) were included. Biochemical response was defined as a PSA decline of more than 50% from baseline (PSA-50) within 20 wk after C1. Quality of life was assessed on 2 validated scales. We evaluated the effect of PSA change and 3 imaging parameters (pretreatment PSMA PET SUVmean, pretreatment [18F]FDG PET metabolic tumor volume, and mean total tumor dosimetry on SPECT/CT after C1) with these outcomes and survival time after cycle 2.

Results

Of 195 patients, 103 met inclusion criteria between January 5, 2021, and March 30, 2023, with an early PSA rise in 31 patients (30%) or stable PSA in 72 patients (70%). Of 103 patients, 45 (44%) achieved PSA-50 by 140 d after C1. Seven of 31 patients (23%) and 38 of 72 patients (53%) with early rising and stable PSA, respectively, had achieved a PSA-50 by 140 d after C1. A PSMA SUVmean of 10 or more versus an SUVmean of less than 10 conferred a higher chance of PSA-50 (59% vs. 37%; odds ratio, 2.53; 95% CI, 1.08-5.95). In total, 59 deaths were recorded with a median overall survival of 11.3 mo after cycle 2. [18F]FDG metabolic tumor volume was the only variable to have a meaningful association with overall survival. Patients with baseline pain scores of 10 or greater according to EORTC QLQ-C30 pain or 2 or greater according to BPI-SF had clinically meaningful reductions in pain in 39 of 55 patients (71%) and 17 of 37 patients (46%), respectively.

Conclusion

Discontinuing [177Lu]Lu-PSMA-617 based solely on PSA response after just 1 cycle is not advisable as a substantial number of patients achieve PSA-50 or a reduction in pain. Baseline imaging parameters have prognostic utility and can assist in patient counseling and clinical decision-making.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DipeptidesHeterocyclic Compounds, 1-RingLutetiumProstate-Specific AntigenProstatic Neoplasms, Castration-ResistantRadiopharmaceuticalsAgedAged, 80 and overHumansMaleMiddle AgedNeoplasm MetastasisPrognosisRegistriesTreatment OutcomeRadioisotopes

Stichwörter der Autor:innen

PSMAprostate-specific membrane antigenradiopharmaceutical therapytheranostics

Substanzen

DipeptidesHeterocyclic Compounds, 1-RingLutetiumLutetium-177PluvictoProstate-Specific AntigenPSMA-617RadiopharmaceuticalsRadioisotopes

Autor:innen und Institutionen

  • Prostate Cancer Theranostics and Imaging Centre of Excellence, Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, Parkville, Melbourne, Victoria, Australia.
  • Department of Cancer Surgery, Peter MacCallum Cancer Centre, Parkville, Melbourne, Victoria, Australia.
  • Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Melbourne, Victoria, Australia.
  • Garvan Institute of Medical Research, Darlinghurst, Sydney, New South Wales, Australia.
  • Chaim Sheba Medical Center, Tel HaShomer, Ramat Gan, Tel Aviv District, Israel; and.
  • Department of Medical Oncology, Peter MacCallum Cancer Centre, Parkville, Melbourne, Victoria, Australia.

Zitieren

APA

Chen, D. C., Buteau, J. P., Papa, N., Akhurst, T., Alipour, R., Bollampally, N., Cardin, A., Eifer, M., Casanueva Eliceiry, S., Jackson, P., Jewell, K., Kashyap, R., Kong, G., Kostos, L., Ravi Kumar, A., McIntosh, L., Medhurst, E., Saghebi, J., Sandhu, S., …, & Hofman, M. S. (2025). Prognostic Value of Initial Imaging and PSA Change with [ 177 Lu]Lu-PSMA-617 Radiopharmaceutical Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: A ProsTIC Registry Analysis. Journal of Nuclear Medicine, 66(12), 1914-1920. https://doi.org/10.2967/jnumed.125.270804

Vancouver

Chen DC, Buteau JP, Papa N, Akhurst T, Alipour R, Bollampally N, et al. Prognostic Value of Initial Imaging and PSA Change with [ 177 Lu]Lu-PSMA-617 Radiopharmaceutical Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: A ProsTIC Registry Analysis. Journal of Nuclear Medicine. 2025;66(12):1914-1920. doi:10.2967/jnumed.125.270804

BibTeX
@article{Chen2025,
  author = {Chen, David C and Buteau, James P and Papa, Nathan and Akhurst, Tim and Alipour, Ramin and Bollampally, Neeraja and Cardin, Anthony and Eifer, Michal and Casanueva Eliceiry, Sebastián and Jackson, Price and Jewell, Kerry and Kashyap, Raghava and Kong, Grace and Kostos, Louise and Ravi Kumar, Aravind and McIntosh, Lachlan and Medhurst, Elizabeth and Saghebi, Javad and Sandhu, Shahneen and Murphy, Declan G and Tran, Ben and Azad, Arun A and Hofman, Michael S},
  title = {Prognostic Value of Initial Imaging and PSA Change with [ 177 Lu]Lu-PSMA-617 Radiopharmaceutical Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: A ProsTIC Registry Analysis},
  journal = {Journal of Nuclear Medicine},
  year = {2025},
  volume = {66},
  number = {12},
  pages = {1914--1920},
  doi = {10.2967/jnumed.125.270804}
}
Kostenlos starten →